Persistence of the antibody response to the VlsE sixth invariant region (IR6) peptide of Borrelia burgdorferi after successful antibiotic treatment of lyme disease

Journal of Infectious Diseases

Volumn 187, Issue 8, 2003, Pages 1178-1186

  Peltomaa, Miikka ^a,b,c   McHugh, Gail ^a   Steere, Allen C ^a,c  

^a TUFTS MEDICAL CENTER   (United States)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; BACTERIAL PROTEIN; CEFTRIAXONE; DOXYCYCLINE; IMMUNOGLOBULIN G ANTIBODY; PENICILLIN G; PROTEIN VLSE; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBIOTIC THERAPY; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BORRELIA BURGDORFERI; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHEMA CHRONICUM MIGRANS; FACIAL NERVE PARALYSIS; FEMALE; FOLLOW UP; HUMAN; LYME DISEASE; MALE; PERSISTENT INFECTION; PRIORITY JOURNAL; SERUM;

ADULT; ANTI-BACTERIAL AGENTS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; BORRELIA BURGDORFERI; FEMALE; HUMANS; LIPOPROTEINS; LYME DISEASE; MALE; TIME FACTORS;

EID: 0037447242     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/374376     Document Type: Article

References (26)

1. Steere AC. Lyme disease. N Engl J Med 2001; 345:115-25.
2. Steere AC, Bartenhagen NH, Craft JE, et al. The early clinical manifestations of Lyme disease. Ann Intern Med 1983; 99:76-82.
3. Nadelman RB, Nowakowski J, Forseter G, et al. The clinical spectrum of early Lyme borreliosis in patients with culture-confirmed erythema migrans. Am J Med 1996; 100:502-8.
4. Clark JR, Carlson RD, Sasaki CT, Pachner AR, Steere AC. Facial paralysis in Lyme disease. Laryngoscope 1985; 95:1341-5.
5. Peltomaa M, Pyykkö I, Seppälä I, Viljanen M. Lyme borreliosis and facial paralysis: a prospective analysis of risk factors and outcome. Am J Otolaryngol 2002; 23:125-32.
6. Steere AC, Schoen RT, Taylor E. The clinical evolution of Lyme arthritis. Ann Intern Med 1987; 107:725-31.
7. Logigian EL, Kaplan RF, Steere AC. Chronic neurologic manifestations of Lyme disease. N Engl J Med 1990; 323:1438-44.
8. Wormser GP, Nadelman RB, Dattwyler RJ, et al. Practice guidelines for the treatment of Lyme disease. The Infectious Diseases Society of America. Clin Infect Dis 2000; 31(Suppl 1):1-14.
9. Steere AC, Levin RE, Molloy PJ, et al. Treatment of Lyme arthritis. Arthritis Rheum 1994; 37:878-88.
10. Centers for Disease Control and Prevention. Recommendations for test performance and interpretation from the second National Conference on Serologic Diagnosis of Lyme Disease. MMWR Morb Mortal Wkly Rep 1995; 44:590-1.
11. Liang FT, Steere AC, Marques AR, Johnson BJ, Miller IN, Philipp MT. Sensitive and specific serodiagnosis of Lyme disease by enzyme-linked immunosorbent assay with a peptide based on an immunodominant conserved region of Borrelia burgdorferi VlsE. J Clin Microbiol 1999; 37:3990-6.
12. Zhang JR, Hardham JM, Barbour AG, Norris SJ. Antigenic variation in Lyme disease borreliae by promiscuous recombination of VMP-like sequence cassettes. Cell 1997; 89:275-85.
13. Liang FT, Alvarez AL, Gu Y, Nowling JM, Ramamoorthy R, Philipp MT. An immunodominant conserved region within the variable domain of VlsE, the variable surface antigen of Borrelia burgdorferi. J Immunol 1999; 163:5566-73.
14. Kalish RA, McHugh G, Granquist J, Shea B, Ruthazer R, Steere AC. Persistence of immunoglobulin M or immunoglobulin G antibody responses to Borrelia burgdorferi 10-20 years after active Lyme disease. Clin Infect Dis 2001; 33:780-5.
15. Schroeter AL, Lucas JB, Price EV, Falcone VH. Treatment for early syphilis and reactivity of serologic tests. JAMA 1972; 221:471-6.
16. Fiumara NJ. Treatment of primary and secondary syphilis. Serological response. JAMA 1980; 243:2500-2.
17. 6, a conserved immunodominant region of the VlsE lipoprotein, wanes rapidly after antibiotic treatment of Borrelia burgdorferi infection in experimental animals and in humans. J Infect Dis 2001; 184:870-8.
18. Barony G, Merrifield RB. The peptides: analysis, synthesis and biology. New York, NY: Academic Press, 1980:3-285.
19. Dressler F, Whalen JA, Reinhardt BN, Steere AC. Western blotting in the serodiagnosis of Lyme disease. J Infect Dis 1993; 167:392-400.
20. Logigian EL, Kaplan RF, Steere AC. Successful treatment of Lyme encephalopathy with intravenous ceftriaxone. J Infect Dis 1999; 180:377-83.
21. Steere AC, Hutchinson GJ, Rahn DW, et al. Treatment of the early manifestations of Lyme disease. Ann Intern Med 1983; 99:22-6.
22. Nocton JJ, Dressler F, Rutledge BJ, Rys PN, Persing DH, Steere AC. Detection of Borrelia burgdorferi DNA by polymerase chain reaction in synovial fluid in Lyme arthritis. N Engl J Med 1994; 330:229-34.
23. Weis JJ, McCracken BA, Ma Y, et al. Identification of quantitative trait loci governing arthritis severity and humoral responses in the murine model of Lyme disease. J Immunol 1999; 162:948-56.
24. Barthold SW, de Souza M. Exacerbation of Lyme arthritis in beige mice. J Infect Dis 1995; 172:778-84.
25. Müllegger RR, McHugh G, Ruthazer R, Binder B, Kerl H, Steere AC. Differential expression of cytokine mRNA in skin specimens from patients with erythema migrans or acrodermatitis chronica atrophicans. J Invest Dermatol 2000; 115:1115-23.
26. Brunner M, Sigal LH. Use of serum immune complexes in a new test that accurately confirms early Lyme disease and active infection with Borrelia burgdorferi. J Clin Microbiol 2001; 39:3213-21.